Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

Li, Dunhui; Mastaglia, Frank L; Yau, Wai Yan; Chen, Shengdi; Wilton, Steve D; Akkari, Patrick A

Li, Dunhui; Mastaglia, Frank L; Yau, Wai Yan; Chen, Shengdi; Wilton, Steve D; Akkari, Patrick A.

Afiliação

Li D; Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia.
Mastaglia FL; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Yau WY; College of Nursing and Health, Zhengzhou University, Zhengzhou, China.
Chen S; Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia.
Wilton SD; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
Akkari PA; Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia.

Mov Disord ; 37(11): 2184-2190, 2022 11.

Article em En | MEDLINE | ID: mdl-36036206

Assuntos

Oligonucleotídeos Antissenso; Doença de Parkinson; Humanos; Oligonucleotídeos Antissenso/uso terapêutico; Doença de Parkinson/tratamento farmacológico; Doença de Parkinson/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Oligonucleotídeos Antissenso Limite: Humans Idioma: En Revista: Mov Disord Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google